A real-world data of serum neurofilament light chain in a large cohort of Egyptian multiple sclerosis patients: Hospital-based study

被引：0
作者：
Khedr, Eman M. [1 ,2 ]
Nasreldein, Ahmed [1 ]
El-Deen, Hussein Bahey [4 ]
El-Mokhtar, Mohamed A. [3 ]
Mahmoud, Doaa M. [1 ]
机构：
[1] Assiut Univ, Dept Neurol & Psychiat, Fac Med, Assiut, Egypt
[2] Aswan Univ, Fac Med, Dept Neurol & Psychiat, Aswan, Egypt
[3] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut, Egypt
[4] South Valley Univ, Fac Med, Dept Neurol & Psychiat, Qena, Egypt
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2025年 / 94卷
关键词：
Multiple sclerosis; Smouldering-associated worsening; Neurodegeneration; Serum neurofilament light; chain; PROGRESSION; BIOMARKER;
D O I：
10.1016/j.msard.2025.106286
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background: Serum neurofilament light chain (sNFL) is a promising biomarker for neuroaxonal injury in multiple sclerosis (MS). Traditional clinical and radiological examinations often fail to capture the underlying neurodegeneration, particularly in the absence of clinical relapses or gadolinium-enhanced lesions. This study aims to assess sNFL levels in real-world MS patients who have no evidence of activity, to evaluate the potential of sNFL as a biomarker for smoldering-associated worsening (SAW). Materials and Methods: A cross-sectional study, involved 162 MS patients without evidence of disease activity and 40 healthy, age, sex, and education matched controls (HCs). Patients were classified according to MS subtype, DMT status, and type. sNFL levels were measured using an enzyme-linked immunosorbent assay (ELISA) and levels were compared in each group. Results: sNFL levels were significantly higher in MS patients compared to (HCs) (p < 0.001). Median sNFL levels were lowest in the clinically isolated (CIS) group and steady increase in RRMS and reaching the highest levels in the SPMS group (p < 0.001). Despite a slight decrease in sNFL levels in patients who started DMT for a year or less than in the na & iuml;ve group, sNFL levels were highest in patients who were on DMTs for longer durations (p = 0.003). EDSS score was the sole independent predictor of sNFL levels (B = 0.415, p = 0.002). A cut-off value of 23.25 pg/ml was set to distinguish cases and HCs (92 % specificity and 90 % sensitivity), and 75.48 pg/ml was set to distinguish progressive forms (70.00 % sensitivity and 78.30 % specificity). Conclusion: sNFL is sensitive for detecting subclinical neurodegeneration in the absence of relapse or gadoliniumenhanced lesions, supporting the utility of sNFL measurements into routine clinical practice to improve monitoring and management of MS.
引用
收藏
页数：8
相关论文
共 47 条
[1]  
Abdelhak A., Benkert P., Schaedelin S., Boscardin W.J., Cordano C., Oechtering J., Ananth K., Granziera C., Melie-Garcia L., Montes S.C., Beaudry-Richard A., Achtnichts L., Oertel F.C., Lalive P.H., Leppert D., Muller S., Henry R.G., Pot C., Matthias A., Salmen A., Oksenberg J.R., Disanto G., Zecca C., D'Souza M., Du Pasquier R., Bridel C., Gobbi C., Kappos L., Hauser S.L., Cree B.A.C., Kuhle J., Green A.J., UCSF M.E., Teams T.S.S., Neurofilament light chain elevation and disability progression
[2]  
Aktas O R.A., Huss A., Filser M., Baetge S., Stute N., Gasis M., Lepka K., Goebels N., Senel M., Graf J., Enzinger C., Pinter D., Antoch G., Turowski B., Hartung H.P., Albrecht P., Otto M., Tumani H., Penner I.K., Serum neurofilament light chain: no clear relation to cognition and neuropsychiatric symptoms in stable MS, Neurol. Neuroimmunol. Neuroinflamm., (2020)
[3]  
Amin M., Hersh C.M., Updates and advances in multiple sclerosis neurotherapeutics, Neurodegener. Dis. Manage, 13, 1, pp. 47-70, (2023)
[4]  
Ashfaq A., Neurofilament light chains: a reliable biomarker of disease activity in MS, Mult. Scler. Relat. Disord., 59, (2022)
[5]  
Azevedo C.J., Overton E., Khadka S., Buckley J., Liu S., Sampat M., Kantarci O., Lebrun Frenay C., Siva A., Okuda D.T., Pelletier D., Early CNS neurodegeneration in radiologically isolated syndrome, Neurol. Neuroimmunol. Neuroinflamm., 2, 3, (2015)
[6]  
Bao J., Tu H., Li Y., Sun J., Hu Z., Zhang F., Li J., Diffusion tensor imaging revealed microstructural changes in normal-appearing white matter regions in relapsing–Remitting multiple sclerosis, Front. Neurosci., 16, (2022)
[7]  
Bar-Or A., Montalban X., Hu X., Kropshofer H., Kukkaro P., Coello N., Ludwig I., Willi R., Zalesak M., Ramanathan K., Kieseier B.C., Haring D.A., Bagger M.A., Fox E., Serum neurofilament light trajectories and their relation to subclinical radiological disease activity in relapsing multiple sclerosis patients in the APLIOS trial, Neurol. Ther., 12, 1, pp. 303-317, (2022)
[8]  
Barrero Hernandez F.J., Romero Villarrubia A., Munoz Fernandez C., Guillen Martinez V., Aguilera Del Moral A., Barrios-Lopez J.M., Ramirez Rivas M.A., Galvez Munoz A.J., Pinar Morales R., Real-world study of serum neurofilament light chain levels in Ocrelizumab-treated people with relapsing multiple sclerosis, J. Pers. Med., 14, 7, (2024)
[9]  
Barro C., Benkert P., Disanto G., Tsagkas C., Amann M., Naegelin Y., Leppert D., Gobbi C., Granziera C., Yaldizli O., Michalak Z., Wuerfel J., Kappos L., Parmar K., Kuhle J., Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis, Brain, 141, 8, pp. 2382-2391, (2018)
[10]  
Beltran T.A., Normative values for serum neurofilament light chain in US adults, J. Clin. Neurol., 20, 1, pp. 46-49, (2024)
12345